Erlotinib Tablet, Film Coated
Product Images NDC 31722-265

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Erlotinib (NDC 31722-265). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Camberlogo (Camberlogo)

FDA Label Image

Erlotinibtablets100mgcontainer (Erlotinibtablets100mgcontainer)

Label for Erlotinib Tablets 100 mg film-coated oral tablets by Camber Pharmaceuticals, Inc. Contains 30 tablets. The label includes dosing storage instructions, U.S. contact number, NDC 31722-264-30, and manufacturing details by Hetero Labs Limited, India.*

FDA Label Image

Erlotinibtablets100mgrcarton (Erlotinibtablets100mgrcarton)

Packaging label for Erlotinib Tablets 100 mg, film-coated oral tablets by Camber Pharmaceuticals, Inc. The label shows the NDC 31722-264-30 and indicates a package size of 30 tablets. It includes manufacturer and storage information, prescribing note, and contact number. The label is primarily white with green and black text.*

FDA Label Image

Erlotinibtablets150mgcontainer (Erlotinibtablets150mgcontainer)

Label for Erlotinib Tablets 150 mg, film-coated oral tablets from Camber Pharmaceuticals, Inc. The label features the product name, strength, package size of 30 tablets, and NDC 31722-265-30. It includes storage instructions, a barcode, and manufacturer information for Camber Pharmaceuticals and Hetero Labs Limited in India.*

FDA Label Image

Erlotinibtablets150mgrcarton (Erlotinibtablets150mgrcarton)

Packaging label for Erlotinib Tablets 150 mg by Camber Pharmaceuticals, Inc. The film-coated tablets come in a carton containing 30 tablets. The label includes dosage strength (150 mg), Rx only designation, storage instructions, manufacturer details, and a U.S. contact number. The NDC code displayed is 31722-265-30.*

FDA Label Image

Erlotinibtablets25mgcontainer (Erlotinibtablets25mgcontainer)

Label for Erlotinib Tablets 25 mg film-coated tablets by Camber Pharmaceuticals, Inc. Bottle contains 30 tablets. Includes dosage strength, storage instructions at 20°C to 25°C, and manufacturer details including Hetero Labs Limited, India. Features a barcode and U.S. contact number.*

FDA Label Image

Erlotinibtablets25mgrcarton (Erlotinibtablets25mgrcarton)

Packaging label for ERLOTINIB Tablets 25 mg by Camber Pharmaceuticals, Inc. The label includes the Camber logo, NDC 31722-263-30, and specifies 30 tablets per container. It states Rx only and details storage instructions, dosage note, and contact information. The label has a barcode and batch coding area.*

FDA Label Image

Erlotinibtabletsfigure1 (Erlotinibtabletsfigure1)

A Kaplan-Meier survival curve showing progression-free survival probability over time in months, comparing two groups labeled Chemotherapy and Erlotinib. The x-axis represents duration of progression-free survival in months, and the y-axis represents the survival probability. Below the graph, a table lists the number of patients at risk at various time points for each group.*

FDA Label Image

Erlotinibtabletsfigure2 (Erlotinibtabletsfigure2)

A survival probability Kaplan-Meier curve comparing Erlotinib versus placebo over 36 months. The X-axis represents overall survival in months and the Y-axis shows survival probability. Two lines depict survival trends for patients on Erlotinib and placebo, with a table below indicating patient numbers at risk at various time points for each group.*

FDA Label Image

Erlotinibtabletsfigure3 (Erlotinibtabletsfigure3)

A Kaplan-Meier survival curve chart showing overall survival probability over time (months) comparing two groups of patients treated with Erlotinib versus placebo. The x-axis represents overall survival in months and the y-axis shows survival probability. The chart includes numbers of patients at risk at various time points for both groups.*

FDA Label Image

Erlotinibtabletsfigure4 (Erlotinibtabletsfigure4)

A Kaplan-Meier survival curve chart comparing overall survival probability over time in months for patients treated with Erlotinib versus placebo. The x-axis represents overall survival in months, and the y-axis represents survival probability. Below the graph is a table indicating the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Erlotinibtabletsstructure (Erlotinibtabletsstructure)

Chemical structure of Erlotinib represented with its molecular formula including hydrogen chloride (HCl). The diagram shows the detailed atomic bonds and arrangement typical for this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.